Skip to main content
Lung Cancer
Response to Immune Checkpoint Inhibitors Among Patients with NSCLC with RET Rearrangements
Read More
Lung Cancer
Clinical Trials of Targeted Therapies in RET-Rearranged NSCLC
Read More
Lung Cancer
Unmet Needs in NSCLC
Read More
Ovarian Cancer
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Read More
Ovarian Cancer
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer, PARP Inhibitors
PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy
Read More
Ovarian Cancer
Safety of Approved Rucaparib Starting Dose Confirmed from Pooled Analysis
Read More
Ovarian Cancer
Phase 3 Study to Investigate Anti–PD-1 Antibody in the Treatment of High-Grade Ovarian Cancer
Read More
PARP Inhibitors
The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors
Read More
PARP Inhibitors
The Treatment Landscape in Ovarian Cancer: A Focus on PARP Inhibitors
Read More
Page 131 of 199
Results 1301 - 1310 of 1986